#Pharmaceutical and Novel Drug Delivery conferences 2019

[gastroenterologyucgconferences]

Meet our amazing speaker Dr. Qun Dang will be present his speaker presentation on “Azvudine, a novel nucleoside as effective treatment for HIV and COVID-19 infections with potential for liver cancer.” at the 14GASTROUCG Conference, from December 17-19, 2024 in Holiday Inn Dubai, Al Barsha, UAE & Virtual

As the 14th World Gastroenterology, IBD & Hepatology Conference approaches, the spotlight is on cutting-edge research shaping the future of medicine. Among the most anticipated presentations is Dr. Qun Dang's poster on “Azvudine, a Novel Nucleoside as Effective Treatment for HIV and COVID-19 Infections with Potential for Liver Cancer.”

This innovative research delves into the multifaceted therapeutic potential of Azvudine, a compound poised to revolutionize treatments for infectious diseases and cancer.

A Game-Changer for HIV and COVID-19

Azvudine, a novel nucleoside analog, has shown remarkable efficacy in combating HIV and COVID-19:

HIV: By targeting viral replication, Azvudine provides a new approach to managing HIV, with the potential to enhance treatment regimens.

COVID-19: Amid ongoing challenges in treating SARS-CoV-2, Azvudine has demonstrated significant antiviral activity, offering hope for improved clinical outcomes.

Potential Beyond Infections: Liver Cancer

In addition to its antiviral applications, early studies suggest that Azvudine may have promising anticancer properties. This opens doors to its use in liver cancer, a disease with limited effective treatment options.

Join the Conversation

Dr. Qun Dang’s presentation will provide a comprehensive overview of Azvudine’s mechanisms, clinical data, and its future as a therapeutic agent. This groundbreaking research underscores the importance of collaboration in addressing global health challenges.

Stay tuned for insights from the conference, happening December 15-17, 2023, at the Holiday Inn Dubai, Al Barsha, UAE, and virtually.

About Dr. Qun Dang:

Max received his BS from Jilin University with honors and earned a CGP Chinese national scholarship; he obtained his Ph.D. in organic chemistry from Purdue University in 1992, joined Gensia (later became Metabasis) as a medicinal chemist and worked until 2009 with his last position as director of medicinal chemistry. Max then joined Merck as a Senior Investigator in the External Basic Research department, and then from 2011 to 2013, he was Director of External Medicinal Chemistry, Asia Lead, based in Shanghai facilitating Merck-CRO operations; 2013-2016, he was a Principle Scientist in the exploratory chemistry department at the Kenilworth site. In 2016 he joined Eli Lilly as Asia Head, BD and External Innovation for diabetes and CV research and worked until March 2018 before joining Qilu Pharmaceutical as VP, Global Head of BD and External Innovation with responsibilities for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. From June 2019 to February 2021Max worked at CSPC as corporate VP, President of CSPC Shanghai Research Institute, CEO of InnovStone Therapeutics, responsible for small molecule new drug discovery efforts. In April 2021, Max joined Genuine Biotech as President and responsible for all aspects of company business including corporate strategy, R&D, financing etc. Max has extensive experiences in business development globally and more than 25-years of experiences as a manager of drug discovery programs spanning from early (Target Selection and Validation, Lead Identification) to late (Lead Optimization and candidate selection) stages; led programs that advanced multiple compounds into human clinic trials (two completed Phase 2b POC studies); experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis, anemia, viral and bacterial infections; extensive knowledge of Structure-based Drug Design, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than five years of managing drug discovery programs executed at various CROs. His research activities have led to 91 publications and 60 patents.

Event Details

Date: December 17-19, 2024

Location: Holiday Inn Dubai, Al Barsha, UAE & Virtual You can register here: https://gastroenterology.utilitarianconferences.com/registration

For more information and registration, visit the conference website. Let’s come together to pave the way for a healthier tomorrow!

[yourcientificgroup-blog]

[pharmaphorumuk]

Device advancements to be discussed at the Respiratory Drug Delivery Conference 2019

SMi Reports: New developments for respiratory devices are making headlines ahead of the Respiratory Drug Delivery conference this December

SMi Group are proud to announce the launch of their Respiratory Drug Delivery conference which will take place on 5th – 6th December 2019 in London, UK. The purpose of the two-day agenda is to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs, analysing the success of digital medical devices and connective health technology in aiding the diagnosis of severe asthma and COPD.

In recent news, leading pharmaceutical company, Novartis has developed the first inhaler to be certified under MDR. MDR reviews it as:

“robust and that we assess accurately to the Safety & Performance requirements of the new EU regulations.  Equally importantly, we are on a daily basis increasing the capacity of our reviewer teams; we now have significant capability with experienced very well trained, fully competent experts to undertake MDR reviews. We are confident we can support our large client base in both renewing existing MDD certificates and achieving MDR certification.” (Regulatory Affairs Professionals Society, 2019)

With an increasing number of the population developing respiratory diseases, where in the UK alone has approximately 12.7 million having a history of asthma, COPD or another longstanding respiratory illness, it solidifies the necessity of the Respiratory Drug Delivery Conference. It not only provides the opportunity to network and learn from key opinion leaders regarding the topic, but also an opportunity to jumpstart a conversation on methods of tackling the growing prevalence of respiratory illnesses.

For those interested in attending there is an early bird sale of £300 for bookings made before 30th September. Registrations can be made online at www.respiratorydrugdelivery.com/pharmapr5

Topics for 2019 include:

Assessing the product development and treatment landscape

Evaluating respiratory device design development and novel technologies

Exploring digital connective inhalation

Pricing and reimbursement and the issues associated with pricing pressures of Asthma and COPD inhalers

For the full details and brochure, with the complete agenda and speaker line-up, it is available to download online at www.respiratorydrugdelivery.com/pharmapr5

  Respiratory Drug Delivery

5th – 6th December 2019

Copthorne Tara Hotel, London, UK

For delegate and sponsorship enquiries please contact Alia Malick on +44 (0) 207 827 6168

Reference

Brennan, Z. (2019) ‘Novartis Inhaler is First Device to be Certified Under MDR’, RAPS.org, 11 September

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

The post Device advancements to be discussed at the Respiratory Drug Delivery Conference 2019 appeared first on .

from https://pharmaphorum.com/partner-content/device-advancements-to-be-discussed-at-the-respiratory-drug-delivery-conference-2019/

[kindcongress-blog]

International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems http://kindcongress.com/congress/conference-and-exhibition-on-pharmaceutics/ September 09-10, 2019 |#Osaka, #Japan

[mikemortgage]

IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference

DARTMOUTH, Nova Scotia — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer, Frederic Ors will be making an investor presentation at the 2019 Bloom Burton & Co Healthcare Investor Conference, which will be held from April 30 to May 1, 2019 in Toronto, Ontario.

IMV’s presentation details include:

Date: Wednesday, May 1, 2019

Time: 11:00 a.m. ET

Location: Metro Toronto Convention Centre, 255 Front St W, Toronto, ON

There will be a live webcast of IMV’s presentation accessible in the ‘Events, Webcasts & Presentations’ page of IMV’s website. The webcast will be archived for 90 days following the live presentation and a copy of the presentation will be available www.imv-inc.com.

April 9 H.C. Wainwright Investor Conference Presentation Update:

IMV also revealed a time change for its participation at the H.C. Wainwright Global Life Sciences Conference. IMV will now present at 1:10 p.m. local time. Full details include:

Venue: H.C. Wainwright Global Life Sciences Conference, being held April 7-9, 2019

Date: Tuesday, April 9, 2019

Time: 1:10 p.m. BST

Location: Stratton Suite, Grosvenor House, A JW Marriott Hotel, London, UK

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.

About the Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About Bloom Burton & Co.

Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).

View source version on businesswire.com: https://www.businesswire.com/news/home/20190404005058/en/

Contacts

Investor Relations: Marc Jasmin, IMV Senior Director, Investor Relations and Communications O: (902) 492-1819 ext : 1042 M: (514) 917-9481 E: mjasmin@imv-inc.com Media: Andrea Cohen, Sam Brown Inc. O: (917) 209-7163 E: andreacohen@sambrown.com

from Financial Post https://ift.tt/2OS7g04 via IFTTT Blogger Mortgage Tumblr Mortgage Evernote Mortgage Wordpress Mortgage href="https://www.diigo.com/user/gelsi11">Diigo Mortgage

[millioninsightsreports]

Nanoparticles - Metal & Metal Oxides Market Capacity, Production and Revenue Analysis by 2025 Forecast

25th February 2019: Global Nanoparticles - Metal & Metal Oxides Market size was worth USD 25.86 billion in 2016 which is anticipated to grow at a CAGR of more than 13.7% over the forecast period.

The existence of a significant amount of metal and metal oxide nanoparticle based drugs that are authorized by the U.S. FDA and prescribed by physicians for the treatment of acute and chronic ailments is attributive for the estimated market.

Furthermore, presence of molecules in the development phase based on the principle of metal oxide nanoparticles is anticipated to boost growth in the coming years. Applications served by these particles include radiotherapy enhancement, drug & gene therapy, thermal ablation, and sensitive diagnostic assay.

Get a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/nanoparticles-metal-oxides-in-healthcare-market/request-sample  

This versatile nature with respect to the applicability in health care makes these particles a substantial source of growth in nanomedicine market. Technological innovations pertaining to reduction of adverse effects linked to the application of these particles is expected to influence growth in the forecasted period.

Scientists and biologists are currently involved in directing R&D to improve understanding of metal based nanoparticles in order to lessen the toxicity problems associated with their usage. Subsequent developments are anticipated to fast-track the development over the forecast period.

The pharmaceutical field is a continually progressing marketplace with vigorous regulatory standards, growing demand for outcome oriented therapy and rising manufacturing and R&D costs for delivering better products than the existing ones. These concerns are persistently generating pressure on manufacturers and government policy makers to meet patient expectations for providing better drugs at a low price

Research endeavors carried out for developing novel products is anticipated to boost revenue generation in the coming years. Additionally, the presence of government supported plans such as the National Nanotechnology Initiative (NNI), which offers provision to co-ordinate projects of R&D for nanomedicine technology growth are factors anticipated to strengthen the revenue potential of nanotechnology industry in healthcare.

Type Insights

Gold particles have the biggest share with respect to revenue owing to their vast use in therapeutic advancement. Key factors include small dimensions, less toxicity, and better compatibility that aid in increasing its adoption rate.

 Besides, gold nanocages coupled with the coating of the temperature-sensitive polymer are pertinent in a targeted delivery system that on contact with near-infrared radiations, discharge effectors. These are beneficial in checking for interaction with the drug and avails efficient control, thus driving adoption in the various delivery application of the drugs reaching from DNA to the cellular level, disease monitoring, imaging and diagnosis.

Application Insights

In-vivo imaging is projected to contribute for the largest share in terms of revenue due to growing adoption of nanoshells, for example, Au3Cu1 that claims to provide better contrast for blood vessels which can be used in vivo MR angiography.

Regional Insights

North America dominated with the largest revenue share owing to the existence of clear regulatory guidelines for therapeutic development. Furthermore, with the increasing collaboration between key stake holders including government agencies, lawmakers, health insurers, and pharmacy benefit managers, better outcome based products can be produced with a check on relevance in the market.

This region is also witnessing inter-country collaboration on the production and usage of nanotechnology based products. For example, Canada and the U.S. collaborated on the development of nanomaterials under the Regulatory Co-operation Council (RCC). As a result, the nanotechnology work plan of the region was made and the conference took place in Washington, DC in January 2014.

Asia Pacific is anticipated to exhibit the fastest growth over the forecast period. Factors responsible for the projected CAGR include growing investment in the development of nanoparticles coupled with a surge in the amount of clinical studies that can aid in determination of toxicity of these products.

Corporations across Asia, especially in China and India, are increasing their spending in research projects on the utilization of nanomolecules which is anticipated to support the progression of this market in Asia pacific region.

Competitive Insights

Key companies working for the development of metal and metal oxide nanoparticles include Nanobiotix, AstraZeneca, Pfizer Inc., nanoComposix, Merck KGaA, Nanospectra Biosciences, Immunolight LLC, Women’s Hospital and Brigham.

 Pharma-biotech entities are engaged in R&D and are carrying out enormous capital investments. Product advancement in human therapeutics and rising demand for better outcomes by the treatment provided are anticipated to boost progress in the coming years.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/nanoparticles-metal-oxides-in-healthcare-market  

Market Segment:

Nanoparticles - Metal & Metal Oxides Type Outlook (Revenue, USD Billion, 2013 - 2025)

       • Gold Nanoparticles

       • Silver Nanoparticles

       • Iron Oxide Nanoparticles

       • Alumina Nanoparticles

       • Gadolinium Oxide Nanoparticles

       • Others

Nanoparticles - Metal & Metal Oxides Application Outlook (Revenue, USD Billion, 2013 - 2025)

       • In-vivo Imaging

       • Targeted Drug Delivery

       • Proton Therapy

       • In-vitro Assays

       • Cell & Phantom Imaging

Nanoparticles - Metal & Metal Oxides Regional Outlook (Revenue, USD Billion, 2014 - 2025)

       • North America

           • U.S.

           • Canada

       • Europe

           • Germany

           • UK

       • Asia Pacific

           • Japan

           • China

       • Latin America

           • Brazil

       • Middle East and Africa (MEA)

           • South Africa

For More Information visit https://millioninsightsresearch.blogspot.com  

[maxihealth]

Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results

As Tip O’Neill’s mantra goes, “All politics is local.” In the U.S. 2018 midterm elections, healthcare voting seems to have translated as a local issue, falling into O’Neill’s axiom.

In this election, healthcare was the most important voting issue for consumers, PwC found, ranking above the economy, national security, and education.

On this morning after 2018 midterm election results are (mostly) out, it looks like healthcare was a local and state issue for U.S. 2018 midterm voters. The Democrats flipped more than 23 seats in the U.S. House of Representatives to gain control of that chamber. The Senate is up to 54 seats today, with a runoff to happen in Mississippi, adding to the GOP’s control in that part of the legislative branch.

While we have a divided government via split legislature, one winner in the 2018 midterm outcome is Medicaid.

As I wrote about yesterday (about learning from Governor Kasich), people keen on healthcare should pay attention to the states, which are laboratories for health reform. Governors have health-coverage missions along with managing their portfolios of services for education, infrastructure, and other objectives for state residents. In these midterms, governors flipped from Republican to Democrat in Kansas, Maine and Wisconsin, all of whom promised to expand Medicaid through the Affordable Care Act. Idaho, Nebraska, and Utah voters also opted into Medicaid expansion.

Another healthcare issue that should get traction in this legislative environment is prescription drug pricing. Expect strange bedfellow’ing between House Speaker Nancy Pelosi (D-CA) and President Trump, who has made Rx costs a top priority at least in his healthcare portfolio. Democrats have been committed to the concept of the government negotiating drug prices directly with pharmaceutical companies the way other developed countries do. [Ironically, it’s through those negotiations conducted by other countries on which President Trump and Alex Azar would base their latest proposal to base U.S. pharma costs on reference pricing]. “We want to give President Trump what he said he wanted in the campaign,” Rep. Lloyd Doggett (D-TX) said to the Washington Examiner. Rep. Doggett has been drafting legislation to allow the government such authority for drugs covered by Medicare Part D.

Health Populi’s Hot Points:  How might healthcare play out locally in the next 1-3 years? In the private sector, we’ve been seeing the evolution of retail health beyond the pharmacy, as pharmacy chains and retailers expand services that provide primary and self-care on-ramps to people who want to be active in their own and their families’ healthcare. Walmart announced plans to develop a new town center store concept, and CVS, whose merger with Aetna is expected to be completed by the American Thanksgiving holiday, launched the CarePass loyalty and delivery program (presumably to more effectively compete with Amazon and PillPack), and plans to offer more services in stores in 2019 post-acquisition.

Of course, Amazon continues its march into healthcare, as the company grows into private-label medical devices, private label products (in and outside of healthcare), leverage the PillPack acquisition, and consider its role in primary care services with the hires of staff and thought leaders in the space.

Employers, too, will be nudging insured workers to lower-cost sites of care in 2019, from virtual care via telehealth platforms to retail clinics for flu shots and less-acute care providers.

PwC’s research also learned that consumers would be open to earning rewards and discounts in exchange for accessing services through these new front doors for care, shown in the third chart. Just as consumers’ taste for subscription meal-kits and pet care grow, so might peoples’ interest in bundling services by novel healthcare entrants.

In her post-midterm election public remarks this morning at a press conference, Nancy Pelosi referred to Tip O’Neill’s “all politics is local” creed. She then did a riff on that sentiment, stating that, “All health care is personal.”

For Americans who voted in 2018, health care was top-of-mind on the basis of both access and cost to the family budget. In 2018 and beyond, patients-as-consumers are looking for health care that’s quality and cost-effective. In fact, costs and financial health were actually bundled into the top 3 issues on voters’ minds, cited in the PwC survey above: healthcare, Social Security and Medicare, and the economy, together.

Welcome to the 2020 Presidential campaign season, all 726 left of it.

The post Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results appeared first on HealthPopuli.com.

Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results posted first on https://carilloncitydental.blogspot.com

[realselfblog]

Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results

As Tip O’Neill’s mantra goes, “All politics is local.” In the U.S. 2018 midterm elections, healthcare voting seems to have translated as a local issue, falling into O’Neill’s axiom.

In this election, healthcare was the most important voting issue for consumers, PwC found, ranking above the economy, national security, and education.

On this morning after 2018 midterm election results are (mostly) out, it looks like healthcare was a local and state issue for U.S. 2018 midterm voters. The Democrats flipped more than 23 seats in the U.S. House of Representatives to gain control of that chamber. The Senate is up to 54 seats today, with a runoff to happen in Mississippi, adding to the GOP’s control in that part of the legislative branch.

While we have a divided government via split legislature, one winner in the 2018 midterm outcome is Medicaid.

As I wrote about yesterday (about learning from Governor Kasich), people keen on healthcare should pay attention to the states, which are laboratories for health reform. Governors have health-coverage missions along with managing their portfolios of services for education, infrastructure, and other objectives for state residents. In these midterms, governors flipped from Republican to Democrat in Kansas, Maine and Wisconsin, all of whom promised to expand Medicaid through the Affordable Care Act. Idaho, Nebraska, and Utah voters also opted into Medicaid expansion.

Another healthcare issue that should get traction in this legislative environment is prescription drug pricing. Expect strange bedfellow’ing between House Speaker Nancy Pelosi (D-CA) and President Trump, who has made Rx costs a top priority at least in his healthcare portfolio. Democrats have been committed to the concept of the government negotiating drug prices directly with pharmaceutical companies the way other developed countries do. [Ironically, it’s through those negotiations conducted by other countries on which President Trump and Alex Azar would base their latest proposal to base U.S. pharma costs on reference pricing]. “We want to give President Trump what he said he wanted in the campaign,” Rep. Lloyd Doggett (D-TX) said to the Washington Examiner. Rep. Doggett has been drafting legislation to allow the government such authority for drugs covered by Medicare Part D.

Health Populi’s Hot Points:  How might healthcare play out locally in the next 1-3 years? In the private sector, we’ve been seeing the evolution of retail health beyond the pharmacy, as pharmacy chains and retailers expand services that provide primary and self-care on-ramps to people who want to be active in their own and their families’ healthcare. Walmart announced plans to develop a new town center store concept, and CVS, whose merger with Aetna is expected to be completed by the American Thanksgiving holiday, launched the CarePass loyalty and delivery program (presumably to more effectively compete with Amazon and PillPack), and plans to offer more services in stores in 2019 post-acquisition.

Of course, Amazon continues its march into healthcare, as the company grows into private-label medical devices, private label products (in and outside of healthcare), leverage the PillPack acquisition, and consider its role in primary care services with the hires of staff and thought leaders in the space.

Employers, too, will be nudging insured workers to lower-cost sites of care in 2019, from virtual care via telehealth platforms to retail clinics for flu shots and less-acute care providers.

PwC’s research also learned that consumers would be open to earning rewards and discounts in exchange for accessing services through these new front doors for care, shown in the third chart. Just as consumers’ taste for subscription meal-kits and pet care grow, so might peoples’ interest in bundling services by novel healthcare entrants.

In her post-midterm election public remarks this morning at a press conference, Nancy Pelosi referred to Tip O’Neill’s “all politics is local” creed. She then did a riff on that sentiment, stating that, “All health care is personal.”

For Americans who voted in 2018, health care was top-of-mind on the basis of both access and cost to the family budget. In 2018 and beyond, patients-as-consumers are looking for health care that’s quality and cost-effective. In fact, costs and financial health were actually bundled into the top 3 issues on voters’ minds, cited in the PwC survey above: healthcare, Social Security and Medicare, and the economy, together.

Welcome to the 2020 Presidential campaign season, all 726 left of it.

The post Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results appeared first on HealthPopuli.com.

Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results posted first on http://dentistfortworth.blogspot.com

[titheguerrero]

Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results

As Tip O’Neill’s mantra goes, “All politics is local.” In the U.S. 2018 midterm elections, healthcare voting seems to have translated as a local issue, falling into O’Neill’s axiom.

In this election, healthcare was the most important voting issue for consumers, PwC found, ranking above the economy, national security, and education.

On this morning after 2018 midterm election results are (mostly) out, it looks like healthcare was a local and state issue for U.S. 2018 midterm voters. The Democrats flipped more than 23 seats in the U.S. House of Representatives to gain control of that chamber. The Senate is up to 54 seats today, with a runoff to happen in Mississippi, adding to the GOP’s control in that part of the legislative branch.

While we have a divided government via split legislature, one winner in the 2018 midterm outcome is Medicaid.

As I wrote about yesterday (about learning from Governor Kasich), people keen on healthcare should pay attention to the states, which are laboratories for health reform. Governors have health-coverage missions along with managing their portfolios of services for education, infrastructure, and other objectives for state residents. In these midterms, governors flipped from Republican to Democrat in Kansas, Maine and Wisconsin, all of whom promised to expand Medicaid through the Affordable Care Act. Idaho, Nebraska, and Utah voters also opted into Medicaid expansion.

Another healthcare issue that should get traction in this legislative environment is prescription drug pricing. Expect strange bedfellow’ing between House Speaker Nancy Pelosi (D-CA) and President Trump, who has made Rx costs a top priority at least in his healthcare portfolio. Democrats have been committed to the concept of the government negotiating drug prices directly with pharmaceutical companies the way other developed countries do. [Ironically, it’s through those negotiations conducted by other countries on which President Trump and Alex Azar would base their latest proposal to base U.S. pharma costs on reference pricing]. “We want to give President Trump what he said he wanted in the campaign,” Rep. Lloyd Doggett (D-TX) said to the Washington Examiner. Rep. Doggett has been drafting legislation to allow the government such authority for drugs covered by Medicare Part D.

Health Populi’s Hot Points:  How might healthcare play out locally in the next 1-3 years? In the private sector, we’ve been seeing the evolution of retail health beyond the pharmacy, as pharmacy chains and retailers expand services that provide primary and self-care on-ramps to people who want to be active in their own and their families’ healthcare. Walmart announced plans to develop a new town center store concept, and CVS, whose merger with Aetna is expected to be completed by the American Thanksgiving holiday, launched the CarePass loyalty and delivery program (presumably to more effectively compete with Amazon and PillPack), and plans to offer more services in stores in 2019 post-acquisition.

Of course, Amazon continues its march into healthcare, as the company grows into private-label medical devices, private label products (in and outside of healthcare), leverage the PillPack acquisition, and consider its role in primary care services with the hires of staff and thought leaders in the space.

Employers, too, will be nudging insured workers to lower-cost sites of care in 2019, from virtual care via telehealth platforms to retail clinics for flu shots and less-acute care providers.

PwC’s research also learned that consumers would be open to earning rewards and discounts in exchange for accessing services through these new front doors for care, shown in the third chart. Just as consumers’ taste for subscription meal-kits and pet care grow, so might peoples’ interest in bundling services by novel healthcare entrants.

In her post-midterm election public remarks this morning at a press conference, Nancy Pelosi referred to Tip O’Neill’s “all politics is local” creed. She then did a riff on that sentiment, stating that, “All health care is personal.”

For Americans who voted in 2018, health care was top-of-mind on the basis of both access and cost to the family budget. In 2018 and beyond, patients-as-consumers are looking for health care that’s quality and cost-effective. In fact, costs and financial health were actually bundled into the top 3 issues on voters’ minds, cited in the PwC survey above: healthcare, Social Security and Medicare, and the economy, together.

Welcome to the 2020 Presidential campaign season, all 726 left of it.

The post Healthcare Is Local: Channeling Tip O’Neill in the 2018 Midterm Election Results appeared first on HealthPopuli.com.

Article source:Health Populi

[yourcientificgroup-blog]

Drug Delivery Conferences | Pharma Conferences 2019 | Pharmaceutica 2019

International conference and Exhibition on Pharmaceutics & Novel Drug Delivery systems. we tend to truly invite you to the Pharmaceutica-2019 that goes to be direction all through this Sep 9-10, 2019 at Osaka Japan.

For more info visit our website: https://worldpharmaceuticalmeetings.com/

 For More info:

Mail: jia-xin@globalpharmaceuticalmeetings.com

Contact No: +65 3165 4229

Follow us on:

Twitter: https://twitter.com/Drug_Delivery

Linked in: https://www.linkedin.com/in/jia-xin-p-6b3292184/

[yourcientificgroup-blog]

Pharmaceutical Conferences | Drug Delivery Conferences | Medicine Meetings | Singapore Events | Drug Conferences | 2019

We sincerely welcome you to the International Conference on Pharmaceutics and novel drug delivery systems which is going to be held during this July 22-23, 2019 at Singapore. We invite everyone who are keen on sharing their insight and explore in the field of Pharamceutics .

For more info: http://worldpharmaceuticalmeetings.com

[pharmaphorumuk]

Aerie Pharmaceuticals interview released for Ophthalmic Drugs Conference

SMi Group Reports: Vice President of Aerie Pharmaceuticals to present at SMi’s Ophthalmic Drugs conference commencing on 18th– 20th November 2019 in London.

SMi catches up with Aerie Pharmaceuticals Vice President, Chemistry, Mitchell de Long as a speaker for the Ophthalmic Drugs conference taking place on the 18th– 20th November 2019 in London. As Europe’s leading Ophthalmic Drugs conference, the three-day agenda will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort, and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.

Snapshot of Mitchell’s interview:

The ophthalmic drugs market has matured greatly over recent years, what are the key significant developments you have noticed over the past year?

“The launch in the US of Rocklatan is certainly the most significant new development in the past year, as it marks the first approval by the US FDA of a combination drug containing a prostaglandin analogue (PGA).  Also, of note is Allergan’s filing of an NDA in the US for an intracameral implant of bimatoprost, a prostaglandin analogue.  This would mark the first time a PGA would be delivered by injection into the eye, as opposed to by an eyedrop.  Other novel molecules that have launched in the past few years will also prove interesting as they find their niche in a suddenly more crowded marketplace.”

What do you personally see as the greatest challenge to overcome in the field of Ophthalmic Drugs at the moment?

“Since the last flurry of new ophthalmic drugs was launched, the reimbursement situation in the US has become much more complex and poses a significant challenge to the US launch of new drugs…”

For the full speaker interview, speaker line-up and more content including the latest brochure and past attendees, it is available to download at www.ophthalmicdrugs.com/pr5

Proudly sponsored by: EXPERIMENTICA | ProMed Pharma

Contacts:

Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 / amalick@smi-online.co.uk

Media enquiries contact Neill Howard +44 (0) 207 827 6164 / nhoward@smi-online.co.uk

The post Aerie Pharmaceuticals interview released for Ophthalmic Drugs Conference appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/partner-content/aerie-pharmaceuticals-interview-released-for-ophthalmic-drugs-conference/

[pharmaphorumuk]

Registration is now open for the Pre-filled Syringes and Injectable devices Conference

SMi Reports: Registration is open for SMi Group’s 12th annual conference and exhibition taking place in January 2020 in London.

As Europe’s leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year’s programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director – Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products ,Senior Pharmaceutical Assessor and many more.

BENEFITS OF ATTENDING:

Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design

Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices

Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery

Assess industry case studies exploring how to overcome challenges of extractables and leachables

View the full agenda and speaker line-up online: www.pre-filled-syringes.com/pharmapr1

Registration is live on the website and a saving of £400 is available for bookings made before 30th September 2019.

Plus, pre-conference workshop day will be taking place on 14th January in London:

Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards

Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH

Workshop C: Extractables and Leachables: Considerations for PFS Platforms

  Pre-Filled Syringes and Injectable Drug Devices

15th – 16th January 2020

London, UK

www.pre-filled-syringes.com/pharmapr1

— ENDS –

Contact Information:

For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email:  hsidhu@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

The post Registration is now open for the Pre-filled Syringes and Injectable devices Conference appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/partner-content/registration-is-now-open-for-the-pre-filled-syringes-and-injectable-devices-conference/

[pharmaphorumuk]

Key Opinion Leaders to present at the Respiratory Drug Delivery Conference

SMi Reports: Learn from key opinion leaders at the Respiratory Drug Delivery conference this December

SMi Group are delighted to announce their inaugural conference Respiratory Drug Delivery, taking place on 5th – 6th December 2019 in London, UK.

The conference aims to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs, analysing the success of digital medical devices and connective health technology in aiding the diagnosis of severe asthma and COPD.

This year, attendees will have the opportunity to network and learn from key opinion leaders including:

Dr Alison Moore, Clinical Development Manager, GSK

Ph.D Gunilla Petersson, Science and Innovation Director, Astrazeneca

Mr Herbert Wachtel, Senior Principal Scientist, Boehringer Ingelheim

Mr Mark Milton-Edwards, Head of Product & Health Solutions, Digital Health, Teva Pharmaceuticals

Dr Orla Ni Ogain, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)

Professor Tim Higenbottam, President of the Faculty of Pharmaceutical Medicine, Faculty of Pharmaceutical Medicine

Mr Mayur Patel, Leading innovative medical and combination product development, PA Consulting

Dr Dave Lewis, Aerosol Science Director, Chiesi Ltd

Professor Chris Corrigan, Professor of Asthma, Allergy and Immunology, Kings College London

Dr Jorge Bernardino de la Serna, Senior Lecturer, Inhalation, Toxicology and Pharmacology, Imperial College London

Ms Aljoscha Koenneke, PhD Pharmacist, Institute of Biopharmaceutics and Pharmaceutical Technology, Saarland University

The final brochure, with the full agenda and speaker line-up, is available to download online at http://www.respiratorydrugdelivery.com/pharmapr4

Plus, key conference highlights for 2019 include:

Hear updates from pharmaceutical companies on assessing the strategies to transform disease management through drug combinations, devices and inhaled biologic treatments

Discuss the issues associated within pricing pressure of Asthma and COPD inhalation products

Explore the current novel technologies and therapeutics aimed to optimize the delivery of respiratory drugs such as nanoparticle-based drug delivery

Gain insight into the strategies being implemented to digital connective inhalation to improve patient adherence

For those interested in attending the conference, an early bird sale of £300 is available for bookings made before 30th September. Registrations can be made online at http://www.respiratorydrugdelivery.com/pharmapr4

Respiratory Drug Delivery

5th – 6th December 2019

Copthorne Tara Hotel, London, UK

For delegate enquiries please contact Fateja Begum on +44 (0) 20 7827 6184 or fbegum@smi-online.co.uk

For sponsorship enquiries please contact Alia Malick on +44 (0) 207 827 6168 or amalick@smi-online.co.uk

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

The post Key Opinion Leaders to present at the Respiratory Drug Delivery Conference appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/partner-content/key-opinion-leaders-to-present-at-the-respiratory-drug-delivery-conference/

[pharmaphorumuk]

Pre-Filled Syringes and Injectable Drug Devices 2020

Assessing the regulatory environment and future of PFS design and development

SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London on 15th and 16th January 2020.

As Europe’s leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year’s programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director – Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products ,Senior Pharmaceutical Assessor and many more.

BENEFITS OF ATTENDING:

Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design

Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices

Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery

Assess industry case studies exploring how to overcome challenges of extractables and leachables

View the full agenda and speaker line-up online: www.pre-filled-syringes.com/pharmapwl

Plus, pre-conference workshop day will be taking place on 14th January in London:

Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards

Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH

Workshop C: Extractables and Leachables: Considerations for PFS Platforms

EARLY-BIRD RATES:

BOOK BY 30TH SEPTEMBER AND SAVE £400

BOOK BY 31ST OCTOBER AND SAVE £200

BOOK BY 29TH NOVEMBER AND SAVE £100

Registrations can be made on the event website at: www.pre-filled-syringes.com/pharmapwl

Chairs for 2019:

James Mellman, Device Manager, Novartis

Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers:

Abha Raveau-Violette, Device Manager, AstraZeneca

Amanda Matthews, Senior Director, Pfizer

Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT

Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG

Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson

Cinzia Rotella, Senior Materials Scientist, Sanofi

Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer

Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals

Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc

James Mellman, Device Manager, Novartis A G

Kewei Yang, Pharmaceutical Scientist, Roche

Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc

Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)

Matthew Nicolas, Investigator, GlaxoSmithKline

Nicolas Eon, Senior Global Product Manager, SCHOTT

Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH

Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals

Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences

Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Additional Contact Info:

T: +44 (0)20 7827 6088

E: hsidhu@smi-online.co.uk

Follow us:  @SMiPharm #PFSSMi

The post Pre-Filled Syringes and Injectable Drug Devices 2020 appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/events/pre-filled-syringes-and-injectable-drug-devices-2020/

[pharmaphorumuk]

Three Interactive Sessions to take place at the Respiratory Drug Delivery Conference

SMi Reports: The 2019 Respiratory Drug Delivery conference to host three interactive sessions this December.

The Respiratory Drug Delivery, taking place in London on 5th-6th December, will be hosting three interactive sessions as part of the two-day conference.

Topics for the 2019 event include:

Assessing novel technologies in improving respiratory drug delivery

Improving collaborative efforts and partnership to uncover novel drug target and meet the unmet needs of patients

Analysing current product design and development from both a safety and efficacy perspective but all those of the Quality-by-Design perspective

Adhering to regulatory updates within the global respiratory market

This year, SMi aims to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs.

The brochure with the two-day agenda and speaker line-up is available to download online at www.respiratorydrugdelivery.com/pharmapr3

Interactive Session: “Assessing an Effective Road Map in Managing Partnerships in Inhalers”

When it comes to effective management of partnerships between the person with asthma and the healthcare team, it’s important to understand and assess the key considerations. Education should be an integral part of all interactions between patient & HCP.

This session will assess the road map in managing and developing an effective road map for managing partnerships in inhalers.

Interactive Session: “Novel Approaches to characterise Aerosol Dynamics”

Introductory overview and case studies highlighting the reality of different characterisation approaches

Assessing Drug Delivery methods, discussing mechanisms and dynamic breakup

Reviewing the effects of the lung environment, including heat and relative humidity

Why do dynamics matter in drug delivery?

Analysing the importance of novel approaches to characterize aerosol dynamics

Interactive Session: “Device Discovery: How relevant is a device to the patient?”

Inhaled therapy ensures rapid and direct delivery to the site of pathology and can be provided to patients via a range of devices, including nebulizers, pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs).

Despite the wide availability of these devices, poor inhaler technique and non-adherence to inhaled therapy has a marked effect on the therapeutic benefit of medication for asthma and COPD. This interactive discussion will assess the real-word study challenges.

There is an early bird saving of £300 available for bookings place before 30th September. Registrations can be made online at www.respiratorydrugdelivery.com/pharmapr3

  Respiratory Drug Delivery

5th – 6th December 2019

Copthorne Tara Hotel, London, UK

For delegate enquiries please contact Fateja Begum on +44 (0) 20 7827 6184 or fbegum@smi-online.co.uk

For sponsorship enquiries please contact Alia Malick on +44 (0) 207 827 6168 or amalick@smi-online.co.uk

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

The post Three Interactive Sessions to take place at the Respiratory Drug Delivery Conference appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/partner-content/three-interactive-sessions-to-take-place-at-the-respiratory-drug-delivery-conference/